Piramal Pharma Limited

Total Valuation

Piramal Pharma Limited carries a market capitalization of 236.11B, placing it among publicly traded companies globally. Its enterprise value stands at 264.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Piramal Pharma Limited trades at a trailing price-to-earnings ratio of 269.44.

Enterprise Valuation

On an enterprise value basis, Piramal Pharma Limited trades at an EV/EBITDA multiple of 51.02 and an EV/FCF ratio of 255.94. The EV/Sales ratio of 2.89 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 51.02 provides insight into valuation relative to core operating earnings.

Financial Position

Piramal Pharma Limited maintains a current ratio of 2.57, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 120.30, indicating elevated leverage, while an interest coverage ratio of 1.29 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Piramal Pharma Limited has paid 2.83B in income taxes, reflecting an effective tax rate of 74.24.

Stock Price Statistics

Piramal Pharma Limited's stock has declined approximately -12.14815% over the past 52 weeks. The 50-day moving average sits at 169.46, while the 200-day moving average is 170.94.

Income Statement

Over the trailing twelve months, Piramal Pharma Limited generated 91.34B in revenue and converted that into 980.70M in net income, yielding earnings per share of 0.75. EBITDA reached 5.18B, while operating income came in at 5.18B.

Margins

Piramal Pharma Limited operates with a gross margin of 64.40, reflecting its pricing power and cost economics. The operating margin of 5.67 and net profit margin of 1.07 provide insight into operational efficiency.

Stock Splits

Piramal Pharma Limited's most recent stock split took place on August 2, 2023 with a 1000:1023 split ratio.

Scores

Piramal Pharma Limited posts an Altman Z-Score of 7.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.